Harvard Bioscience (HBIO) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.67 --0%
EPS Growth %: -800.0%
Financial Fact:
Amortization of intangible assets: 729K
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: -800.0%
Financial Fact:
Amortization of intangible assets: 729K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q2 EPS of $0.06, in-line with the analyst estimate of $0.06. Revenue for the quarter came in at $25.4 million versus the consensus estimate of $25.46 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Twin Disc (TWIN) Tops Q1 EPS by 13c
- U.S. private payrolls rise by 86,000 in October, ADP says
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
